

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Hepatocellular carcinoma: recent advances and... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-620/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-620" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Hepatocellular carcinoma: recent advances and emerging medical therapies" />
    
            <meta name="og:title" content="F1000Research Article: Hepatocellular carcinoma: recent advances and emerging medical therapies.">
            <meta name="og:description" content="Read the latest article version by Kwan-Lung Ko, Lung-Yi Mak, Ka-Shing Cheung, Man-Fung Yuen, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="27074">
            <meta name="article-id" content="24543">
            <meta name="dc.title" content="Hepatocellular carcinoma: recent advances and emerging medical therapies">
            <meta name="dc.description" content="Hepatocellular carcinoma remains a deadly disease with poor prognosis in patients with unresectable cancer. Trans-arterial chemoembolization is the primary locoregional therapy for intermediate-stage hepatocellular carcinoma, with an estimated median overall survival of less than two years. For almost a decade, sorafenib has been the only standard systemic treatment for metastatic disease or tumors which progress or are considered unsuitable for locoregional therapy. Major breakthroughs have been made over the past few years in the management of hepatocellular carcinoma, especially in medical therapies for advanced disease. In this article, recent advances in intra-arterial therapy, multi-kinase inhibitors, and immunotherapy will be reviewed.">
            <meta name="dc.subject" content="hepatocellular carcinoma, medical therapy">
            <meta name="dc.creator" content="Ko, Kwan-Lung">
            <meta name="dc.creator" content="Mak, Lung-Yi">
            <meta name="dc.creator" content="Cheung, Ka-Shing">
            <meta name="dc.creator" content="Yuen, Man-Fung">
            <meta name="dc.date" content="2020/06/17">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.24543.1">
            <meta name="dc.source" content="F1000Research 2020 9:620">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="hepatocellular carcinoma">
            <meta name="prism.keyword" content="medical therapy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/06/17">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="620">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.24543.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-620">
            <meta name="citation_title" content="Hepatocellular carcinoma: recent advances and emerging medical therapies">
            <meta name="citation_abstract" content="Hepatocellular carcinoma remains a deadly disease with poor prognosis in patients with unresectable cancer. Trans-arterial chemoembolization is the primary locoregional therapy for intermediate-stage hepatocellular carcinoma, with an estimated median overall survival of less than two years. For almost a decade, sorafenib has been the only standard systemic treatment for metastatic disease or tumors which progress or are considered unsuitable for locoregional therapy. Major breakthroughs have been made over the past few years in the management of hepatocellular carcinoma, especially in medical therapies for advanced disease. In this article, recent advances in intra-arterial therapy, multi-kinase inhibitors, and immunotherapy will be reviewed.">
            <meta name="citation_description" content="Hepatocellular carcinoma remains a deadly disease with poor prognosis in patients with unresectable cancer. Trans-arterial chemoembolization is the primary locoregional therapy for intermediate-stage hepatocellular carcinoma, with an estimated median overall survival of less than two years. For almost a decade, sorafenib has been the only standard systemic treatment for metastatic disease or tumors which progress or are considered unsuitable for locoregional therapy. Major breakthroughs have been made over the past few years in the management of hepatocellular carcinoma, especially in medical therapies for advanced disease. In this article, recent advances in intra-arterial therapy, multi-kinase inhibitors, and immunotherapy will be reviewed.">
            <meta name="citation_keywords" content="hepatocellular carcinoma, medical therapy">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Kwan-Lung Ko">
            <meta name="citation_author_institution" content="Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong">
            <meta name="citation_author" content="Lung-Yi Mak">
            <meta name="citation_author_institution" content="Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong">
            <meta name="citation_author" content="Ka-Shing Cheung">
            <meta name="citation_author_institution" content="Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong">
            <meta name="citation_author" content="Man-Fung Yuen">
            <meta name="citation_author_institution" content="Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong">
            <meta name="citation_author_institution" content="State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong">
            <meta name="citation_publication_date" content="2020/06/17">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="620">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.24543.1">
            <meta name="citation_firstpage" content="620">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-620/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-620.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=27074 /> <input type=hidden id=articleId name=articleId value=24543 /> <input type=hidden id=xmlUrl value="/articles/9-620/v1/xml"/> <input type=hidden id=xmlFileName value="-9-620-v1.xml"> <input type=hidden id=article_uuid value=035be9ea-c7e2-4c84-9410-e9e2ac6bf73d /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Hepatocellular carcinoma: recent advances and emerging medical therapies"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.24543.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.24543.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-620"
  },
  "headline": "Hepatocellular carcinoma: recent advances and emerging medical therapies",
  "datePublished": "2020-06-17T09:05:00",
  "dateModified": "2020-06-17T09:05:00",
  "author": [
    {
      "@type": "Person",
      "name": "Kwan-Lung Ko"
    },    {
      "@type": "Person",
      "name": "Lung-Yi Mak"
    },    {
      "@type": "Person",
      "name": "Ka-Shing Cheung"
    },    {
      "@type": "Person",
      "name": "Man-Fung Yuen"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Hepatocellular carcinoma remains a deadly disease with poor prognosis in patients with unresectable cancer. Trans-arterial chemoembolization is the primary locoregional therapy for intermediate-stage hepatocellular carcinoma, with an estimated median overall survival of less than two years. For almost a decade, sorafenib has been the only standard systemic treatment for metastatic disease or tumors which progress or are considered unsuitable for locoregional therapy. Major breakthroughs have been made over the past few years in the management of hepatocellular carcinoma, especially in medical therapies for advanced disease. In this article, recent advances in intra-arterial therapy, multi-kinase inhibitors, and immunotherapy will be reviewed."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-620/v1",
            "name": "Hepatocellular carcinoma: recent advances and emerging medical therapies"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Hepatocellular carcinoma: recent advances and emerging medical therapies </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=27074 data-id=24543 data-downloads="" data-views="" data-scholar="10.12688/f1000research.24543.1" data-recommended="" data-doi="10.12688/f1000research.24543.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-620/v1/pdf?article_uuid=035be9ea-c7e2-4c84-9410-e9e2ac6bf73d" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-24543-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-24543-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-24543-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Ko KL, Mak LY, Cheung KS and Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):620 (<a class=new-orange href="https://doi.org/10.12688/f1000research.24543.1" target=_blank>https://doi.org/10.12688/f1000research.24543.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-24543-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=24543 id=track-article-signin-24543 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/24543?target=/articles/9-620/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=27074 /> <input name=articleId type=hidden value=24543 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Hepatocellular carcinoma: recent advances and emerging medical therapies</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Kwan-Lung Ko<a href="https://orcid.org/0000-0003-3302-639X" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3302-639X</div><sup>1</sup>,&nbsp;</span><span class="">Lung-Yi Mak<sup>1</sup>,&nbsp;</span><span class="">Ka-Shing Cheung<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:mfyuen@hkucc.hku.hk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Man-Fung Yuen</span></a><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Kwan-Lung Ko<a href="http://orcid.org/0000-0003-3302-639X" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3302-639X</div><sup>1</sup>,&nbsp;</span><span class="">Lung-Yi Mak<sup>1</sup>,&nbsp;</span><span class="">Ka-Shing Cheung<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:mfyuen@hkucc.hku.hk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Man-Fung Yuen</span></a><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 17 Jun 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.24543.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong<br/> <sup>2</sup> State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong<br/> <p> <div class=margin-bottom> Kwan-Lung Ko <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Lung-Yi Mak <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Ka-Shing Cheung <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Man-Fung Yuen <br/> <span>Roles: </span> Conceptualization, Project Administration, Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=58952-65020></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=69446-65021></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Hepatocellular carcinoma remains a deadly disease with poor prognosis in patients with unresectable cancer. Trans-arterial chemoembolization is the primary locoregional therapy for intermediate-stage hepatocellular carcinoma, with an estimated median overall survival of less than two years. For almost a decade, sorafenib has been the only standard systemic treatment for metastatic disease or tumors which progress or are considered unsuitable for locoregional therapy. Major breakthroughs have been made over the past few years in the management of hepatocellular carcinoma, especially in medical therapies for advanced disease. In this article, recent advances in intra-arterial therapy, multi-kinase inhibitors, and immunotherapy will be reviewed. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> hepatocellular carcinoma, medical therapy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Man-Fung Yuen (<a href="mailto:mfyuen@hkucc.hku.hk">mfyuen@hkucc.hku.hk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Man-Fung Yuen </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Ko KL <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Ko KL, Mak LY, Cheung KS and Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):620 (<a href="https://doi.org/10.12688/f1000research.24543.1" target=_blank>https://doi.org/10.12688/f1000research.24543.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 17 Jun 2020, <b>9</b>(F1000 Faculty Rev):620 (<a href="https://doi.org/10.12688/f1000research.24543.1" target=_blank>https://doi.org/10.12688/f1000research.24543.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 17 Jun 2020, <b>9</b>(F1000 Faculty Rev):620 (<a href="https://doi.org/10.12688/f1000research.24543.1" target=_blank>https://doi.org/10.12688/f1000research.24543.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d11518e182>Introduction</h2><p class="" id=d11518e185>Among all cancers globally, liver cancer ranked the sixth in incidence and the fourth in mortality, accounting for 841,080 new cases and 781,631 deaths worldwide in 2018<sup><a href="#ref-1">1</a></sup>. Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer, with risk factors including hepatitis B virus (HBV) and hepatitis C virus (HCV) infection as well as cirrhosis of any etiology such as alcoholic liver disease, non-alcoholic steatohepatitis, and primary biliary cholangitis. Diagnosis of HCC is usually made by contrast enhanced imaging. Barcelona Clinic Liver Cancer (BCLC) staging remains the most commonly used staging system<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>. BCLC staging incorporates tumor burden, liver reserve, and performance status and classifies HCC into very early stage (0), early stage (A), intermediate stage (B), advanced stage (C), and terminal stage (D)<sup><a href="#ref-4">4</a></sup>. The management strategy can then be recommended according to different stages of disease<sup><a href="#ref-2">2</a></sup>. Recently, a popular staging system, the Hong Kong liver cancer staging system (HKLC), which is derived from a group of Hong Kong experts<sup><a href="#ref-5">5</a></sup>, was introduced. According to this study, it has a better discriminating power than BCLC<sup><a href="#ref-6">6</a></sup>. Nevertheless, it is noteworthy that BCLC is derived from mostly HCV-related HCC cases, while HKLC is derived from an Asian cohort where HBV is the predominant risk factor for HCC. Surgical resection, tumor ablation, and liver transplantation are curative treatments indicated for very early and early stage HCC. Owing to a lack of widely implemented HCC surveillance programs in many parts of the world, most patients are unfortunately diagnosed at an advanced stage, precluding curative therapy<sup><a href="#ref-7">7</a></sup>.</p><p class="" id=d11518e220>Non-surgical management for HCC includes locoregional intra-arterial therapy, systemic treatment with multi-kinase inhibitors, and immunotherapy. Recent advances and emerging strategies in these modalities to improve the outcome of HCC will be reviewed.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d11518e226>Intra-arterial therapy</h2><div class=section><a name=d11518e229 class=n-a></a><h3 class=section-title>Trans-arterial chemoembolization</h3><p class="" id=d11518e234>Trans-arterial chemoembolization (TACE) is the most popular form of intra-arterial therapy and is the established first-line treatment for intermediate-stage HCC<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>. It involves arterial catheterization, usually via the femoral artery, to cannulate the hepatic arterial branches. Cytotoxic agent, usually doxorubicin or cisplatin, is then delivered to the highly vascularized liver tumor. It is followed by blocking of the feeding vessel with an embolization agent, commonly lipiodol, to induce ischemic necrosis of the tumor. The rest of the liver parenchyma is relatively preserved as a result of dual blood supply from both the portal vein and the hepatic artery<sup><a href="#ref-8">8</a></sup>. Significant improvement of survival was shown in patients with locally advanced HCC and Child-Pugh A or B cirrhosis treated with TACE as compared with best supportive care, with relative risk of death reduction more than 50%<sup><a href="#ref-9">9</a>–<a href="#ref-11">11</a></sup> (<a href="#T1">Table 1</a>). Post-embolization syndrome, liver failure due to ischemic damage, biliary injury, gastroduodenal ulceration, and renal dysfunction are potential complications of TACE. Acute liver decompensation may occur in up to one-fifth of patients undergoing TACE<sup><a href="#ref-12">12</a></sup>. Dosage of cytotoxic agent, baseline liver function as reflected by bilirubin and prothrombin time, and stage of cirrhosis are identified risk factors. Absolute contraindications to TACE include decompensated cirrhosis, renal failure, main portal vein obstruction, extensive tumor burden, and technical difficulties<sup><a href="#ref-13">13</a></sup>. Despite gradual improvement in efficacy and survival, patient selection for the initiation of TACE, the evaluation of tumor response, and the decision on the frequency and duration of therapy are not standardized because of marked heterogeneity within the group of intermediate-stage HCC<sup><a href="#ref-14">14</a></sup>. The Hepatoma Arterial-Embolization Prognostic (HAP) score, Assessment for Retreatment with TACE (ART) score, and selection for TACE treatment (STATE) score are prognostic scores derived from combinations of tumor diameter, radiological response, alpha-fetoprotein (AFP) level, and liver biochemistry (bilirubin, aspartate aminotransferase [AST], and C-reactive protein) to better stratify and select patients for the initiation of or subsequent TACE<sup><a href="#ref-15">15</a>–<a href="#ref-18">18</a></sup>. However, controlled studies are required to determine whether implementing the prognostic scores in addition to BCLC staging can further improve treatment response and survival in patients receiving TACE. In addition, better definition of TACE failure is also needed, as it correlates with patient survival and mandates switching TACE to an alternative treatment strategy.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Trials on intra-arterial therapies for hepatocellular carcinoma.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d11518e289 class=n-a></a><thead><a name=d11518e291 class=n-a></a><tr><a name=d11518e293 class=n-a></a><th colspan=1 rowspan=1><a name=d11518e295 class=n-a></a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d11518e297 class=n-a></a>Study arm</th><th align=left colspan=1 rowspan=1 valign=top><a name=d11518e300 class=n-a></a>Control arm</th><th align=left colspan=1 rowspan=1 valign=top><a name=d11518e303 class=n-a></a>No. of<br class=br>patients</th><th align=left colspan=1 rowspan=1 valign=top><a name=d11518e308 class=n-a></a>Outcome</th><th align=left colspan=1 rowspan=1 valign=top><a name=d11518e312 class=n-a></a>Major side effects for study<br class=br>arm</th></tr></thead><tbody><a name=d11518e319 class=n-a></a><tr><a name=d11518e321 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e322 class=n-a></a>Llovet <i>et al</i>.<sup><a href="#ref-9">9</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e331 class=n-a></a>Embolization arm:<br class=br>gelatin sponge<br class=br>Chemoembolization<br class=br>arm: gelatin sponge plus<br class=br>doxorubicin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e342 class=n-a></a>Placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e345 class=n-a></a>112</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e348 class=n-a></a>Mean survival 25.3 versus 28.7<br class=br>versus 17.9 months; HR 0.47,<br class=br>95% CI 0.25–0.91,<br class=br><i>P</i> = 0.025 for chemoembolization<br class=br>versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e361 class=n-a></a>Cholecystitis, leucopenia,<br class=br>ischemic biliary and liver injury,<br class=br>infection, allergic dermatitis,<br class=br>alopecia</td></tr><tr><a name=d11518e370 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e371 class=n-a></a>Lo <i>et al</i>.<sup><a href="#ref-10">10</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e380 class=n-a></a>TACE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e383 class=n-a></a>Placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e386 class=n-a></a>79</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e389 class=n-a></a>Estimated 1-, 2-, and 3-year<br class=br>survival 57%, 31%, and 26%<br class=br>versus 32%, 11%, and 3%<br class=br>RR of death 0.50, 95% CI<br class=br>0.31–0.81, <i>P</i> = 0.005</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e403 class=n-a></a>Fever, abdominal pain, vomiting, ascites</td></tr><tr><a name=d11518e406 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e407 class=n-a></a>Yuen <i>et al</i>.<sup><a href="#ref-11">11</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e416 class=n-a></a>TACE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e419 class=n-a></a>Conservative<br class=br>care</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e424 class=n-a></a>96</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e427 class=n-a></a>Mean survival 31.2 versus 14.1<br class=br>months, <i>P</i> = 0.0126</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e435 class=n-a></a>Hepatic decompensation</td></tr><tr><a name=d11518e438 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e439 class=n-a></a>Lammer <i>et al</i>.<sup><a href="#ref-19">19</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e448 class=n-a></a>DEB-TACE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e451 class=n-a></a>TACE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e454 class=n-a></a>212</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e457 class=n-a></a>Tumor response at 6 months<br class=br>51.6% versus 43.5%, <i>P</i> = 0.110<br class=br>for superiority </td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e467 class=n-a></a>Significant reduction in liver<br class=br>toxicity and doxorubicin-related<br class=br>side effects in DEB-TACE arm</td></tr><tr><a name=d11518e474 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e475 class=n-a></a>Salem <i>et al</i>.<sup><a href="#ref-21">21</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e484 class=n-a></a>Y90 radioembolization</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e487 class=n-a></a>TACE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e490 class=n-a></a>179</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e493 class=n-a></a>Time to progression &gt;26 versus<br class=br>6.8 months, <i>P</i> = 0.001</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e501 class=n-a></a>Less diarrhea and<br class=br>hypoalbuminemia in Y90 arm</td></tr><tr><a name=d11518e507 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e508 class=n-a></a>Kudo <i>et al</i>.<sup><a href="#ref-22">22</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e517 class=n-a></a>TACE plus sorafenib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e520 class=n-a></a>TACE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e523 class=n-a></a>156</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e526 class=n-a></a>Median PFS 25.2 versus 13.5<br class=br>months, <i>P</i> = 0.006<br class=br>Median TTUP 26.7 versus 20.6<br class=br>months, <i>P</i> = 0.020</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e541 class=n-a></a>Thrombocytopenia, hand-foot-<br class=br>skin reaction, hypertension,<br class=br>increased lipase and amylase,<br class=br>neutropenia, fatigue, diarrhea,<br class=br>erythema multiforme more<br class=br>common in study arm</td></tr><tr><a name=d11518e554 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e555 class=n-a></a>Ricke <i>et al</i>.<sup><a href="#ref-23">23</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e564 class=n-a></a>SIRT plus sorafenib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e567 class=n-a></a>Sorafenib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e570 class=n-a></a>424</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e573 class=n-a></a>Median survival 12.1 versus<br class=br>11.4 months; HR 1.01, 95% CI<br class=br>0.81–1.25, <i>P</i> = 0.953</td><td align=left colspan=1 rowspan=1 valign=top><a name=d11518e583 class=n-a></a>Hyperbilirubinemia and fatigue<br class=br>more common in study arm</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d11518e592 class=n-a></a><p id=d11518e594> CI, confidence interval; DEB-TACE, TACE with drug-eluting beads; HR, hazard ratio; PFS, progression-free survival; RR, relative risk; TACE, trans-arterial chemoembolization; TTUP, time to TACE untreatable progression; SIRT, selective internal radiation therapy; Y90, yttrium-90.</p></div></div></div></div><div class=section><a name=d11518e601 class=n-a></a><h3 class=section-title>Other forms of intra-arterial therapy</h3><p class="" id=d11518e606>TACE with drug-eluting beads (DEB-TACE) and trans-arterial radio-embolization (TARE) are alternative intra-arterial locoregional therapies for HCC (<a href="#T1">Table 1</a>). In DEB-TACE, cytotoxin-carrying microspheres are used instead of lipiodol, allowing simultaneous delivery of chemotherapeutic and embolization agents. The potential advantage of DEB-TACE is more sustained and selective drug delivery to the tumor with less systemic absorption and toxicity. However, evidence thus far does not show a clear benefit of DEB-TACE over conventional TACE. The PRECISION V trial is a phase II randomized trial comparing tumor response between DEB-TACE and TACE in 212 patients with unresectable HCC. Superiority in the primary endpoint of tumor response rate at 6 months was not met (51.6% for DEB-TACE versus 43.5% for TACE, <i>P</i> = 0.110 for superiority), but a significant reduction in liver toxicity and doxorubicin-related side effects was seen in the DEB-TACE arm<sup><a href="#ref-19">19</a></sup>. TARE is a form of selective internal radiation therapy (SIRT), in which radioactive Yttrium-90 (Y90) microspheres are introduced into the tumor vasculature. The main anti-tumor effect in TARE is achieved by radiation instead of embolization. As the patency of the hepatic artery is maintained, TARE can be used in HCC with main portal vein invasion or thrombosis, which is considered a contraindication for conventional TACE. A meta-analysis of eight studies involving 1,500 patients demonstrated superiority of TARE over TACE in overall survival (OS), 3-year OS, time to progression (TTP), and hospitalization days<sup><a href="#ref-20">20</a></sup>. A subsequent phase II randomized trial also showed significantly longer TTP in the TARE group compared with conventional TACE (&gt;26 months versus 6.8 months, <i>P</i> &lt;0.01)<sup><a href="#ref-21">21</a></sup>. However, improvement of OS was not shown. A randomized controlled trial comparing DEB-TACE and TARE is currently underway (NCT01381211).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d11518e635>Multi-kinase inhibitors</h2><p class="" id=d11518e638>Tumor cell proliferation, differentiation, and angiogenesis are postulated to be mediated by multiple intracellular and cell surface protein kinases with their downstream pathways, as depicted in <a href="#f1">Figure 1</a><sup><a href="#ref-24">24</a></sup>. Sorafenib, an inhibitor of platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), rearrange during transfection (RET), and C-kit, is the first multi-kinase inhibitor proved to be beneficial in unresectable, advanced-stage HCC. The SHARP trial is the first phase III, placebo-controlled trial of the use of sorafenib in HCC. In this landmark study involving 602 patients with advanced disease naïve to systemic treatment, median OS was significantly improved in the sorafenib group compared to the placebo group (10.7 versus 7.9 months, <i>P</i> &lt;0.001)<sup><a href="#ref-25">25</a></sup>. Another multi-national randomized controlled trial in the Asia-Pacific region, where chronic hepatitis B is the major risk factor for HCC, also confirmed the findings in the SHARP study<sup><a href="#ref-26">26</a></sup>. Further analysis of the two randomized controlled trials identified HCV-related HCC, absence of extrahepatic spread, and low neutrophil-to-lymphocyte ratio as predictors of greater survival benefit with sorafenib<sup><a href="#ref-27">27</a></sup>. The remarkable result with sorafenib is considered a major breakthrough in more than 30 years of pursuing a systemic treatment for HCC. However, the therapeutic window is narrow with sorafenib, with restrictions to patients with good performance status and compensated cirrhosis. Also, dose-limiting side effects including hand-foot-skin reaction, diarrhea, and weight loss are not uncommon. However, recent studies have shown an association between dermatological adverse effects with sorafenib with better treatment outcomes<sup><a href="#ref-28">28</a>,<a href="#ref-29">29</a></sup>. Over subsequent years, other agents have been studied as alternative first-line treatments against sorafenib or as second-line treatments against placebo in patients intolerant to or who have progressed while on sorafenib. Sunitinib, brivanib, linifanib, everolimus, and tivantinib were unable to meet their respective study end points as either non-inferior or superior to sorafenib or show survival benefit in those who failed sorafenib<sup><a href="#ref-30">30</a>–<a href="#ref-34">34</a></sup>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27074/3bddc951-fbf2-4d9c-9bbe-b22cf83a3e63_figure1.gif"><img alt="3bddc951-fbf2-4d9c-9bbe-b22cf83a3e63_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27074/3bddc951-fbf2-4d9c-9bbe-b22cf83a3e63_figure1.gif"></a><div class=caption><h3>Figure 1. Potential treatment targets for systemic therapy in hepatocellular carcinoma.</h3><p id=d11518e687>CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; ERK, extracellular-signal-regulated kinase; FGFR, fibroblast growth factor receptor; MEK, mitogen-activated protein kinase/ERK kinase; PD-1, programmed cell death protein 1; PDGFR, platelet-derived growth factor receptor; PD-L1, programmed death ligand-1; RET, rearrange during transfection; VEGFR, vascular endothelial growth factor receptor.</p></div></div><p class="" id=d11518e694>Lenvatinib, an inhibitor of epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), VEGFR, PDGFR, RET, and C-kit, emerged almost a decade after sorafenib as an alternative first-line treatment for advanced HCC. Non-inferiority to sorafenib in terms of OS (13.6 versus 12.3 months, 95% confidence interval [CI] 0.79–1.06) was demonstrated in the REFLECT trial<sup><a href="#ref-35">35</a></sup>. In patients who progressed while on sorafenib, regorafenib and cabozantinib prolonged survival in their respective phase III randomized controlled trials (<a href="#T2">Table 2</a>). Bruix <i>et al</i>. demonstrated that regorafenib treatment resulted in longer median survival than placebo (10.6 versus 7.8 months; hazard ratio [HR] 0.63, <i>P</i> &lt;0.001)<sup><a href="#ref-36">36</a></sup>. Comparable improvement in median OS was shown with cabozantinib by Abou-Alfa <i>et al</i>. (10.2 versus 8.0 months; HR 0.76, <i>P</i> = 0.005)<sup><a href="#ref-37">37</a></sup>. The recombinant IgG1 monoclonal antibody ramucirumab, which inhibits type 2 VEGFR-mediated angiogenesis, is the latest approved agent for advanced HCC. The initial REACH trial using ramucirumab failed to demonstrate benefit over placebo in patients with BCLC stage B and C disease not amenable to locoregional therapy and treated with first-line sorafenib<sup><a href="#ref-38">38</a></sup>. However, the effect of ramucirumab was noted to correlate with baseline AFP level, and benefit in OS was seen in the subgroup of patients with baseline AFP concentration above 400 ng/ml. The finding formed the basis of the follow-up REACH-2 trial, in which only sorafenib-treated patients with baseline serum AFP concentration over 400 ng/ml were recruited. Median OS (8.5 versus 7.3 months; HR 0.71, <i>P</i> = 0.020) and progression-free survival (PFS) (2.8 versus 1.6 months; HR 0.45, <i>P</i> &lt;0.001) were significantly improved in the ramucirumab group compared with the placebo group<sup><a href="#ref-39">39</a></sup>. The study also highlighted that HCC is a heterogeneous disease and that stratification with biomarkers such as AFP is important in the future development of cancer therapy.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Phase III trials on first- and second-line systemic therapy in hepatocellular carcinoma.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d11518e751 class=n-a></a><thead><a name=d11518e753 class=n-a></a><tr><a name=d11518e755 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d11518e757 class=n-a></a>Trial name</th><th align=left colspan=1 rowspan=1><a name=d11518e760 class=n-a></a>Study drug</th><th align=left colspan=1 rowspan=1><a name=d11518e763 class=n-a></a>Control</th><th align=left colspan=1 rowspan=1><a name=d11518e766 class=n-a></a>No. of<br class=br>patients</th><th align=left colspan=1 rowspan=1><a name=d11518e771 class=n-a></a>Median overall survival<br class=br>(months)</th><th align=left colspan=1 rowspan=1><a name=d11518e777 class=n-a></a>Major side effects of study drug</th></tr></thead><tbody><a name=d11518e782 class=n-a></a><tr><a name=d11518e784 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e786 class=n-a></a> <b>First line</b> </td><td colspan=1 rowspan=1><a name=d11518e792 class=n-a></a></td><td colspan=1 rowspan=1><a name=d11518e794 class=n-a></a></td><td colspan=1 rowspan=1><a name=d11518e796 class=n-a></a></td><td colspan=1 rowspan=1><a name=d11518e798 class=n-a></a></td><td colspan=1 rowspan=1><a name=d11518e801 class=n-a></a></td></tr><tr><a name=d11518e804 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e806 class=n-a></a>SHARP</td><td align=left colspan=1 rowspan=1><a name=d11518e809 class=n-a></a>Sorafenib</td><td align=left colspan=1 rowspan=1><a name=d11518e812 class=n-a></a>Placebo</td><td align=left colspan=1 rowspan=1><a name=d11518e815 class=n-a></a>602</td><td align=left colspan=1 rowspan=1><a name=d11518e818 class=n-a></a>10.7 versus 7.9<br class=br>HR 0.69, 95% CI 0.55–0.87,<br class=br><i>p</i>&lt;0.001</td><td align=left colspan=1 rowspan=1><a name=d11518e828 class=n-a></a>Diarrhea, weight loss, hand-<br class=br>foot-skin reaction, and<br class=br>hypophosphatemia</td></tr><tr><a name=d11518e836 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e838 class=n-a></a>REFLECT</td><td align=left colspan=1 rowspan=1><a name=d11518e841 class=n-a></a>Lenvatinib</td><td align=left colspan=1 rowspan=1><a name=d11518e844 class=n-a></a>Sorafenib</td><td align=left colspan=1 rowspan=1><a name=d11518e847 class=n-a></a>954</td><td align=left colspan=1 rowspan=1><a name=d11518e850 class=n-a></a>13.6 versus 12.3<br class=br>HR 0.92, 95% CI 0.79–1.06,<br class=br>non-inferiority met</td><td align=left colspan=1 rowspan=1><a name=d11518e858 class=n-a></a>Hypertension, diarrhea,<br class=br>decreased appetite, and<br class=br>decreased weight</td></tr><tr><a name=d11518e866 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e868 class=n-a></a>IMbrave150</td><td align=left colspan=1 rowspan=1><a name=d11518e871 class=n-a></a>Atezolizumab plus<br class=br>bevacizumab</td><td align=left colspan=1 rowspan=1><a name=d11518e876 class=n-a></a>Sorafenib</td><td align=left colspan=1 rowspan=1><a name=d11518e879 class=n-a></a>501</td><td align=left colspan=1 rowspan=1><a name=d11518e882 class=n-a></a>Not estimated versus 13.2<br class=br>HR 0.58, 95% CI 0.42–0.79,<br class=br><i>p</i>&lt;0.001</td><td align=left colspan=1 rowspan=1><a name=d11518e892 class=n-a></a>Hypertension, proteinuria,<br class=br>Increase AST, decrease platelet</td></tr><tr><a name=d11518e898 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e900 class=n-a></a>Checkmate-459</td><td align=left colspan=1 rowspan=1><a name=d11518e903 class=n-a></a>Nivolumab</td><td align=left colspan=1 rowspan=1><a name=d11518e906 class=n-a></a>Sorafenib</td><td align=left colspan=1 rowspan=1><a name=d11518e909 class=n-a></a>743</td><td align=left colspan=1 rowspan=1><a name=d11518e912 class=n-a></a>16.4 versus 14.7<br class=br>HR 0.85, 95% CI 0.72–1.0,<br class=br><i>p</i>=0.0752</td><td align=left colspan=1 rowspan=1><a name=d11518e922 class=n-a></a>Not yet published</td></tr><tr><a name=d11518e927 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e929 class=n-a></a>HIMALAYA</td><td align=left colspan=1 rowspan=1><a name=d11518e932 class=n-a></a>Durvalumab plus<br class=br>tremelimumab</td><td align=left colspan=1 rowspan=1><a name=d11518e937 class=n-a></a>Sorafenib</td><td align=left colspan=1 rowspan=1><a name=d11518e940 class=n-a></a>Ongoing</td><td align=left colspan=1 rowspan=1><a name=d11518e943 class=n-a></a>–</td><td align=left colspan=1 rowspan=1><a name=d11518e947 class=n-a></a>–</td></tr><tr><a name=d11518e951 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e953 class=n-a></a>LEAP-002</td><td align=left colspan=1 rowspan=1><a name=d11518e956 class=n-a></a>Lenvatinib plus<br class=br>pembrolizumab</td><td align=left colspan=1 rowspan=1><a name=d11518e961 class=n-a></a>Lenvatinib</td><td align=left colspan=1 rowspan=1><a name=d11518e964 class=n-a></a>Ongoing</td><td align=left colspan=1 rowspan=1><a name=d11518e967 class=n-a></a>–</td><td align=left colspan=1 rowspan=1><a name=d11518e971 class=n-a></a>–</td></tr><tr><a name=d11518e975 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e977 class=n-a></a>COSMIC-312</td><td align=left colspan=1 rowspan=1><a name=d11518e980 class=n-a></a>Cabozantinib plus<br class=br>atezolizumab</td><td align=left colspan=1 rowspan=1><a name=d11518e985 class=n-a></a>Sorafenib</td><td align=left colspan=1 rowspan=1><a name=d11518e988 class=n-a></a>Ongoing</td><td align=left colspan=1 rowspan=1><a name=d11518e991 class=n-a></a>–</td><td align=left colspan=1 rowspan=1><a name=d11518e995 class=n-a></a>–</td></tr><tr><a name=d11518e999 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e1001 class=n-a></a>ORIENT-32</td><td align=left colspan=1 rowspan=1><a name=d11518e1004 class=n-a></a>Sintilimab plus IBI305</td><td align=left colspan=1 rowspan=1><a name=d11518e1007 class=n-a></a>Sorafenib</td><td align=left colspan=1 rowspan=1><a name=d11518e1010 class=n-a></a>Ongoing</td><td align=left colspan=1 rowspan=1><a name=d11518e1013 class=n-a></a>–</td><td align=left colspan=1 rowspan=1><a name=d11518e1017 class=n-a></a>–</td></tr><tr><a name=d11518e1021 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e1023 class=n-a></a>NCT03764293</td><td align=left colspan=1 rowspan=1><a name=d11518e1026 class=n-a></a>Apatinib plus SHR-1210</td><td align=left colspan=1 rowspan=1><a name=d11518e1029 class=n-a></a>Sorafenib</td><td align=left colspan=1 rowspan=1><a name=d11518e1032 class=n-a></a>Ongoing</td><td align=left colspan=1 rowspan=1><a name=d11518e1035 class=n-a></a>–</td><td align=left colspan=1 rowspan=1><a name=d11518e1039 class=n-a></a>–</td></tr><tr><a name=d11518e1043 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e1045 class=n-a></a> <b>Second line</b> </td><td colspan=1 rowspan=1><a name=d11518e1051 class=n-a></a></td><td colspan=1 rowspan=1><a name=d11518e1053 class=n-a></a></td><td colspan=1 rowspan=1><a name=d11518e1055 class=n-a></a></td><td colspan=1 rowspan=1><a name=d11518e1057 class=n-a></a></td><td colspan=1 rowspan=1><a name=d11518e1060 class=n-a></a></td></tr><tr><a name=d11518e1064 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e1066 class=n-a></a>RESORCE</td><td align=left colspan=1 rowspan=1><a name=d11518e1069 class=n-a></a>Regorafenib</td><td align=left colspan=1 rowspan=1><a name=d11518e1072 class=n-a></a>Placebo</td><td align=left colspan=1 rowspan=1><a name=d11518e1075 class=n-a></a>573</td><td align=left colspan=1 rowspan=1><a name=d11518e1078 class=n-a></a>10.6 versus 7.8<br class=br>HR 0.63, 95% CI 0.50–0.79,<br class=br><i>p</i>&lt;0.001</td><td align=left colspan=1 rowspan=1><a name=d11518e1088 class=n-a></a>Hypertension, hand-foot-skin<br class=br>reaction, fatigue, diarrhea</td></tr><tr><a name=d11518e1094 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e1096 class=n-a></a>CELESTIAL</td><td align=left colspan=1 rowspan=1><a name=d11518e1099 class=n-a></a>Cabozantinib</td><td align=left colspan=1 rowspan=1><a name=d11518e1102 class=n-a></a>Placebo</td><td align=left colspan=1 rowspan=1><a name=d11518e1105 class=n-a></a>707 </td><td align=left colspan=1 rowspan=1><a name=d11518e1108 class=n-a></a>10.2 versus 8.0<br class=br>HR 0.76, 95% CI 0.63–0.92,<br class=br><i>p</i>=0.005 </td><td align=left colspan=1 rowspan=1><a name=d11518e1118 class=n-a></a>Palmar-plantar<br class=br>erythrodysesthesia, hypertension,<br class=br>increased AST, fatigue, diarrhea</td></tr><tr><a name=d11518e1126 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e1128 class=n-a></a>REACH-2</td><td align=left colspan=1 rowspan=1><a name=d11518e1131 class=n-a></a>Ramucirumab</td><td align=left colspan=1 rowspan=1><a name=d11518e1134 class=n-a></a>Placebo</td><td align=left colspan=1 rowspan=1><a name=d11518e1137 class=n-a></a>292</td><td align=left colspan=1 rowspan=1><a name=d11518e1140 class=n-a></a>8.5 versus 7.3<br class=br>HR 0.71, 95% CI 0.531–0.949,<br class=br><i>p</i>=0.0199</td><td align=left colspan=1 rowspan=1><a name=d11518e1150 class=n-a></a>Hypertension, hyponatremia,<br class=br>increased AST</td></tr><tr><a name=d11518e1156 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e1158 class=n-a></a>KEYNOTE-240</td><td align=left colspan=1 rowspan=1><a name=d11518e1161 class=n-a></a>Pembrolizumab</td><td align=left colspan=1 rowspan=1><a name=d11518e1164 class=n-a></a>Placebo</td><td align=left colspan=1 rowspan=1><a name=d11518e1167 class=n-a></a>413</td><td align=left colspan=1 rowspan=1><a name=d11518e1170 class=n-a></a>13.9 versus 10.6<br class=br>HR 0.781, 95% CI 0.611–<br class=br>0.998, non-significant at<br class=br>prespecified threshold</td><td align=left colspan=1 rowspan=1><a name=d11518e1180 class=n-a></a>Increased ALT/AST, increased<br class=br>bilirubin</td></tr><tr><a name=d11518e1186 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d11518e1188 class=n-a></a>KEYNOTE-394</td><td align=left colspan=1 rowspan=1><a name=d11518e1191 class=n-a></a>Pembrolizumab</td><td align=left colspan=1 rowspan=1><a name=d11518e1194 class=n-a></a>Placebo</td><td align=left colspan=1 rowspan=1><a name=d11518e1197 class=n-a></a>Ongoing</td><td align=left colspan=1 rowspan=1><a name=d11518e1200 class=n-a></a>–</td><td align=left colspan=1 rowspan=1><a name=d11518e1204 class=n-a></a>–</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d11518e1212 class=n-a></a><p id=d11518e1214> AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; HR, hazard ratio.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d11518e1223>Immunotherapy</h2><p class="" id=d11518e1226>The past decade has witnessed major breakthroughs in cancer immunotherapy, which has demonstrated benefit in various solid organ and hematological malignancies<sup><a href="#ref-40">40</a></sup>. HCC develops in an inflammatory milieu, and immune tolerance is reported to play an important role in tumor pathogenesis<sup><a href="#ref-41">41</a>,<a href="#ref-41">41</a></sup>. Immune checkpoint inhibitors (ICPIs) targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) pathway and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) pathway are the two most studied immunotherapy mechanisms in HCC (<a href="#f1">Figure 1</a>). The two pathways are believed to act at different stages of the immune response. The PD-1/PD-L1 pathway promotes immune tolerance by suppressing the activity of T cells and mediating the differentiation of regulatory T cells, while the CTLA-4 pathway prevents autoimmunity by inhibiting the proliferation of potential autoreactive T cells<sup><a href="#ref-43">43</a>,<a href="#ref-44">44</a></sup>. By inhibiting these immune checkpoints, self-tolerance to malignant cells is lost, resulting in immune-mediated clearance of tumor tissue.</p><div class=section><a name=d11518e1250 class=n-a></a><h3 class=section-title>CTLA-4 inhibitors</h3><p class="" id=d11518e1255>CTLA-4 blockage with tremelimumab is the first checkpoint inhibitor being evaluated as a potential treatment for hepatitis C-related HCC. A phase II study found that tremelimumab exhibits both anti-tumor and antiviral activities, with an acceptable safety profile<sup><a href="#ref-45">45</a></sup>.</p></div><div class=section><a name=d11518e1263 class=n-a></a><h3 class=section-title>PD-1/PD-L1 inhibitors</h3><p class="" id=d11518e1268>Nivolumab is a monoclonal antibody inhibiting PD-1 receptor and demonstrated a favorable response rate of 20% in the dose expansion and escalation study (CheckMate 040)<sup><a href="#ref-46">46</a></sup>. The median OS in sorafenib-experienced patients in this phase II study was 16.7 months with an overall response rate of 14.5%. A similar response rate and improvements in OS, objective response rate, and complete response rate were confirmed in the subsequent head-to-head comparison against sorafenib as first-line therapy in advanced HCC (CheckMate 459), but the primary endpoint of OS did not reach statistical significance<sup><a href="#ref-47">47</a></sup>.</p><p class="" id=d11518e1279>Pembrolizumab is another anti-PD-1 monoclonal antibody being investigated as a potential treatment for advanced HCC. In the phase II Keynote-224 trial, an objective response was observed in 18 of 104 sorafenib-experienced patients (17%), including one complete and 17 partial responses<sup><a href="#ref-48">48</a></sup>. A consistent result was seen in the Keynote-240 study, a follow-up phase III randomized controlled trial comparing pembrolizumab with best supportive care as second-line therapy after sorafenib, but the co-primary endpoint of improvement in OS and PFS was not met<sup><a href="#ref-49">49</a></sup>. A similar phase III study using pembrolizumab in Asian subjects is being conducted (Keynote-394, NCT03062358).</p></div><div class=section><a name=d11518e1291 class=n-a></a><h3 class=section-title>CTLA-4 and PD-1/PD-L1 combination</h3><p class="" id=d11518e1296>Studies have also looked into a potential synergistic effect with combined inhibition of PD-1 and CTLA-4 pathways. Tremelimumab together with the anti-PD-L1 monoclonal antibody durvalumab have demonstrated favorable anti-tumor activity with acceptable tolerability in a small pilot study involving patients with advanced HCC or biliary tract carcinomas<sup><a href="#ref-50">50</a></sup>. A phase III multicenter randomized study (HIMALAYA, NCT03298451) is currently underway testing the dual therapy against sorafenib as first-line treatment in patients with unresectable HCC. The combination of nivolumab and the CTLA-4-inhibiting antibody ipilimumab also showed efficacy with a median OS of 23 months in its dose-finding study<sup><a href="#ref-51">51</a></sup>.</p><p class="" id=d11518e1307>The side effect profile of ICPIs is diverse and distinctive from conventional cytotoxic chemotherapy. The immune-related adverse reactions can affect virtually any organ but most commonly involve the endocrine system, skin, gastrointestinal tract, and liver. For grade 1 toxicity, such as mild endocrinopathy, ICPIs can be continued with close monitoring and hormone replacement. Grade 2 or above toxicity usually mandates interruption of ICPIs with or without the need for steroids and immunosuppressants<sup><a href="#ref-52">52</a></sup>. Compared with patients with melanoma and non-small-cell lung cancer, HCC patients tend to have more elevation of AST/alanine aminotransferase when given ICPIs<sup><a href="#ref-53">53</a></sup>. It can be difficult to differentiate hepatitis associated with ICPIs from other causes of deranged liver function such as disease progression, reactivation of concurrent viral hepatitis, or decompensation of underlying cirrhosis.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d11518e1322>Combination of therapies of different mechanisms</h2><p class="" id=d11518e1325>Investigators have brought together locoregional therapy with systemic therapy or systemic therapy of different classes with the hope of augmenting tumor response. The initial experience with adding sorafenib or other molecular targeted therapy to TACE was disappointing<sup><a href="#ref-54">54</a></sup>. Inadequate dose and duration of sorafenib in these trials were identified as key reasons for failure. The Japanese TACTICS trial eventually demonstrated superiority of TACE plus sorafenib over TACE alone in terms of longer PFS (25.2 versus 13.5 months, <i>P</i> = 0.006) and longer time to TACE untreatable progression (26.7 versus 20.6 months, <i>P</i> = 0.020)<sup><a href="#ref-22">22</a></sup>. The SORAMIC study looked into the combination of sorafenib and SIRT with Y90 compared with sorafenib alone for advanced HCC. The primary endpoint of OS was not met, but subgroup analysis of non-cirrhotic patients or patients aged under 65 years did show a survival benefit with combination therapy<sup><a href="#ref-23">23</a></sup>. Future trials should address issues such as timing of sorafenib administration in relation to intra-arterial therapy, patient selection for such combination therapy by balancing potential benefits with incremental adverse effects, and more precise definition of both treatment efficacy and failure.</p><p class="" id=d11518e1346>The combination of atezolizumab, an anti-PD-L1 antibody, and bevacizumab, an anti-VEGF antibody, has been investigated as a first-line systemic therapy in unresectable or metastatic HCC. It is postulated that the anti-angiogenic and immunomodulatory effect of bevacizumab can augment the anti-tumor immune activity of atezolizumab, as shown by a partial response rate of 62% in the phase I trial<sup><a href="#ref-55">55</a></sup>. Encouraging results were recently reported from the phase III IMbrave 150 trial comparing the dual therapy with sorafenib, in which statistically significant improvement in both OS and PFS was shown (HR of OS 0.58, <i>P</i> &lt;0.001 and HR of PFS 0.59, <i>P</i> &lt;0.001)<sup><a href="#ref-56">56</a></sup>.</p><p class="" id=d11518e1363>Additional phase III trials on combinations of systemic therapies including lenvatinib and pembrolizumab (NCT03713593), cabozantinib and atezolizumab (NCT03755791), sintilimab and IBI305 (NCT0379440), and apatinib and SHR1210 (NCT03764293) are currently ongoing (<a href="#T2">Table 2</a>).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d11518e1373>Conclusion</h2><p class="" id=d11518e1376>HCC remains a deadly disease, and unresectable HCC is associated with limited survival. Considerable advancement in local and systemic therapies has been achieved in recent years owing to better understanding of the tumor microenvironment and the interplay between the tumor and the host immune system. With the latest breakthrough achieved with ICPIs, the armamentarium of treatment for HCC is rapidly expanding. However, heterogeneity in patient selection and definition of treatment response in the existing literature make the application of trial results to real-world practice difficult. With the standardization of trial design, prognostic markers of treatment response can be identified, allowing the selection of patients for the most appropriate anti-tumor therapy. Future studies should also continue to utilize therapeutic agents of different classes to achieve synergistic activity while minimizing toxicity.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d11518e1383 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading is-hidden"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d11923>References</h2><div class="section ref-list"><a name=d11518e1383 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d11518e1390 class=n-a></a>Bray F, Ferlay J, Soerjomataram I, <i> et al.</i>: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J Clin.</i> 2018; <b>68</b>(6): 394–424. <a target=xrefwindow id=d11518e1401 href="http://www.ncbi.nlm.nih.gov/pubmed/30207593">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1404 href="https://doi.org/10.3322/caac.21492">Publisher Full Text </a></span><div class=note><a name=d11518e1406 class=n-a></a><p class=first id=d11518e1407><a target=xrefwindow href="https://facultyopinions.com/prime/734004835" id=d11518e1408>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d11518e1417 class=n-a></a>Marrero JA, Kulik LM, Sirlin CB, <i> et al.</i>: Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology.</i> 2018; <b>68</b>(2): 723–50. <a target=xrefwindow id=d11518e1428 href="http://www.ncbi.nlm.nih.gov/pubmed/29624699">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1431 href="https://doi.org/10.1002/hep.29913">Publisher Full Text </a></span><div class=note><a name=d11518e1433 class=n-a></a><p class=first id=d11518e1434><a target=xrefwindow href="https://facultyopinions.com/prime/733031123" id=d11518e1435>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d11518e1444 class=n-a></a>European Association for the Study of the LiverGalle Peter R, Forner Alejandro: EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>J Hepatol.</i> 2018; <b>69</b>(1): 182–236. <a target=xrefwindow id=d11518e1452 href="http://www.ncbi.nlm.nih.gov/pubmed/29628281">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1455 href="https://doi.org/10.1016/j.jhep.2018.03.019">Publisher Full Text </a></span><div class=note><a name=d11518e1457 class=n-a></a><p class=first id=d11518e1458><a target=xrefwindow href="https://facultyopinions.com/prime/733511632" id=d11518e1459>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d11518e1468 class=n-a></a>Llovet JM, Fuster J, Bruix J: The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. <i>Liver Transpl.</i> 2004; <b>10</b>(2 Suppl 1): S115–20. <a target=xrefwindow id=d11518e1476 href="http://www.ncbi.nlm.nih.gov/pubmed/14762851">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1479 href="https://doi.org/10.1002/lt.20034">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d11518e1488 class=n-a></a>Yau T, Tang VYF, Yao TJ, <i> et al.</i>: Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma. <i>Gastroenterology.</i> 2014; <b>146</b>(7): 1691–1700.e3. <a target=xrefwindow id=d11518e1499 href="http://www.ncbi.nlm.nih.gov/pubmed/24583061">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1502 href="https://doi.org/10.1053/j.gastro.2014.02.032">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d11518e1512 class=n-a></a>Parikh ND, Scaglione S, Li Y, <i> et al.</i>: A Comparison of Staging Systems for Hepatocellular Carcinoma in a Multicenter US Cohort. <i>Clin Gastroenterol Hepatol.</i> 2018; <b>16</b>(5): 781–2. <a target=xrefwindow id=d11518e1523 href="http://www.ncbi.nlm.nih.gov/pubmed/28987503">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1526 href="https://doi.org/10.1016/j.cgh.2017.10.001">Publisher Full Text </a> | <a target=xrefwindow id=d11518e1530 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5913743">Free Full Text </a></span><div class=note><a name=d11518e1532 class=n-a></a><p class=first id=d11518e1533><a target=xrefwindow href="https://facultyopinions.com/prime/735793913" id=d11518e1534>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d11518e1543 class=n-a></a>Francica G, Borzio M: Status of, and strategies for improving, adherence to HCC screening and surveillance. <i>J Hepatocell Carcinoma.</i> 2019; <b>6</b>: 131–41. <a target=xrefwindow id=d11518e1551 href="http://www.ncbi.nlm.nih.gov/pubmed/31440486">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1554 href="https://doi.org/10.2147/JHC.S159269">Publisher Full Text </a> | <a target=xrefwindow id=d11518e1557 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6664854">Free Full Text </a></span><div class=note><a name=d11518e1559 class=n-a></a><p class=first id=d11518e1560><a target=xrefwindow href="https://facultyopinions.com/prime/738017654" id=d11518e1561>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d11518e1570 class=n-a></a>Shin SW: The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. <i>Korean J Radiol.</i> 2009; <b>10</b>(5): 425–34. <a target=xrefwindow id=d11518e1578 href="http://www.ncbi.nlm.nih.gov/pubmed/19721826">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1581 href="https://doi.org/10.3348/kjr.2009.10.5.425">Publisher Full Text </a> | <a target=xrefwindow id=d11518e1584 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2731859">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d11518e1593 class=n-a></a>Llovet JM, Real MI, Montaña X, <i> et al.</i>: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. <i>Lancet.</i> 2002; <b>359</b>(9319): 1734–9. <a target=xrefwindow id=d11518e1604 href="http://www.ncbi.nlm.nih.gov/pubmed/12049862">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1607 href="https://doi.org/10.1016/S0140-6736(02)08649-X">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d11518e1616 class=n-a></a>Lo CM, Ngan H, Tso WK, <i> et al.</i>: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. <i>Hepatology.</i> 2002; <b>35</b>(5): 1164–71. <a target=xrefwindow id=d11518e1627 href="http://www.ncbi.nlm.nih.gov/pubmed/11981766">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1630 href="https://doi.org/10.1053/jhep.2002.33156">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d11518e1639 class=n-a></a>Yuen MF, Chan AO, Wong BC, <i> et al.</i>: Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B results of a comparative study in 96 Chinese patients. <i>Am J Gastroenterol.</i> 2003; <b>98</b>(5): 1181–5. <a target=xrefwindow id=d11518e1650 href="http://www.ncbi.nlm.nih.gov/pubmed/12809846">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1653 href="https://doi.org/10.1111/j.1572-0241.2003.07404.x">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d11518e1663 class=n-a></a>Chan AO, Yuen MF, Hui CK, <i> et al.</i>: A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. <i>Cancer.</i> 2002; <b>94</b>(6): 1747–52. <a target=xrefwindow id=d11518e1674 href="http://www.ncbi.nlm.nih.gov/pubmed/11920537">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1677 href="https://doi.org/10.1002/cncr.10407">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d11518e1686 class=n-a></a>Vogel A, Cervantes A, Chau I, <i> et al.</i>: Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol.</i> 2018; <b>29</b>(Suppl 4): iv238–iv255. <a target=xrefwindow id=d11518e1697 href="http://www.ncbi.nlm.nih.gov/pubmed/30285213">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1700 href="https://doi.org/10.1093/annonc/mdy308">Publisher Full Text </a></span><div class=note><a name=d11518e1702 class=n-a></a><p class=first id=d11518e1703><a target=xrefwindow href="https://facultyopinions.com/prime/734167715" id=d11518e1704>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d11518e1713 class=n-a></a>Sieghart W, Hucke F, Peck-Radosavljevic M: Transarterial chemoembolization: Modalities, indication, and patient selection. <i>J Hepatol.</i> 2015; <b>62</b>(5): 1187–95. <a target=xrefwindow id=d11518e1721 href="http://www.ncbi.nlm.nih.gov/pubmed/25681552">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1724 href="https://doi.org/10.1016/j.jhep.2015.02.010">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d11518e1733 class=n-a></a>Kadalayil L, Benini R, Pallan L, <i> et al.</i>: A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. <i>Ann Oncol.</i> 2013; <b>24</b>(10): 2565–70. <a target=xrefwindow id=d11518e1744 href="http://www.ncbi.nlm.nih.gov/pubmed/23857958">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1747 href="https://doi.org/10.1093/annonc/mdt247">Publisher Full Text </a> | <a target=xrefwindow id=d11518e1751 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4023407">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d11518e1760 class=n-a></a>Sieghart W, Hucke F, Pinter M, <i> et al.</i>: The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Hepatology.</i> 2013; <b>57</b>(6): 2261–73. <a target=xrefwindow id=d11518e1771 href="http://www.ncbi.nlm.nih.gov/pubmed/23316013">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1774 href="https://doi.org/10.1002/hep.26256">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d11518e1783 class=n-a></a>Hucke F, Sieghart W, Pinter M, <i> et al.</i>: The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. <i>J Hepatol.</i> 2014; <b>60</b>(1): 118–26. <a target=xrefwindow id=d11518e1794 href="http://www.ncbi.nlm.nih.gov/pubmed/24012941">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1797 href="https://doi.org/10.1016/j.jhep.2013.08.022">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d11518e1807 class=n-a></a>Hucke F, Pinter M, Graziadei I, <i> et al.</i>: How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. <i>J Hepatol.</i> 2014; <b>61</b>(6): 1287–96. <a target=xrefwindow id=d11518e1818 href="http://www.ncbi.nlm.nih.gov/pubmed/25016222">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1821 href="https://doi.org/10.1016/j.jhep.2014.07.002">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d11518e1830 class=n-a></a>Lammer J, Malagari K, Vogl T, <i> et al.</i>: Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. <i>Cardiovasc Intervent Radiol.</i> 2010; <b>33</b>(1): 41–52. <a target=xrefwindow id=d11518e1841 href="http://www.ncbi.nlm.nih.gov/pubmed/19908093">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1844 href="https://doi.org/10.1007/s00270-009-9711-7">Publisher Full Text </a> | <a target=xrefwindow id=d11518e1848 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2816794">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d11518e1857 class=n-a></a>Zhang Y, Li Y, Ji H, <i> et al.</i>: Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis. <i>Biosci Trends.</i> 2015; <b>9</b>(5): 289–98. <a target=xrefwindow id=d11518e1868 href="http://www.ncbi.nlm.nih.gov/pubmed/26559021">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1871 href="https://doi.org/10.5582/bst.2015.01089">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d11518e1880 class=n-a></a>Salem R, Gordon AC, Mouli S, <i> et al.</i>: Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. <i>Gastroenterology.</i> 2016; <b>151</b>(6): 1155–1163.e2. <a target=xrefwindow id=d11518e1891 href="http://www.ncbi.nlm.nih.gov/pubmed/27575820">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1894 href="https://doi.org/10.1053/j.gastro.2016.08.029">Publisher Full Text </a> | <a target=xrefwindow id=d11518e1898 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5124387">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d11518e1907 class=n-a></a>Kudo M, Ueshima K, Ikeda M, <i> et al.</i>: Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. <i>Gut.</i> 2019. <a target=xrefwindow id=d11518e1915 href="http://www.ncbi.nlm.nih.gov/pubmed/31801872">PubMed Abstract </a></span><div class=note><a name=d11518e1917 class=n-a></a><p class=first id=d11518e1918><a target=xrefwindow href="https://facultyopinions.com/prime/737038142" id=d11518e1919>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d11518e1928 class=n-a></a>Ricke J, Klümpen HJ, Amthauer H, <i> et al.</i>: Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. <i> J Hepatol.</i> 2019; <b>71</b>(6): 1164–74. <a target=xrefwindow id=d11518e1939 href="http://www.ncbi.nlm.nih.gov/pubmed/31421157">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1942 href="https://doi.org/10.1016/j.jhep.2019.08.006">Publisher Full Text </a></span><div class=note><a name=d11518e1944 class=n-a></a><p class=first id=d11518e1945><a target=xrefwindow href="https://facultyopinions.com/prime/736456189" id=d11518e1946>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d11518e1956 class=n-a></a>Cervello M, Bachvarov D, Lampiasi N, <i> et al.</i>: Molecular mechanisms of sorafenib action in liver cancer cells. <i>Cell Cycle.</i> 2014; <b>11</b>(15): 2843–55. <a target=xrefwindow id=d11518e1967 href="http://www.ncbi.nlm.nih.gov/pubmed/22801548">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1970 href="https://doi.org/10.4161/cc.21193">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d11518e1979 class=n-a></a>Llovet JM, Ricci S, Mazzaferro V, <i> et al.</i>: Sorafenib in advanced hepatocellular carcinoma. <i>N Engl J Med.</i> 2008; <b>359</b>(4): 378–90. <a target=xrefwindow id=d11518e1990 href="http://www.ncbi.nlm.nih.gov/pubmed/18650514">PubMed Abstract </a> | <a target=xrefwindow id=d11518e1993 href="https://doi.org/10.1056/NEJMoa0708857">Publisher Full Text </a></span><div class=note><a name=d11518e1996 class=n-a></a><p class=first id=d11518e1997><a target=xrefwindow href="https://facultyopinions.com/prime/1123905" id=d11518e1998>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d11518e2007 class=n-a></a>Cheng AL, Kang YK, Chen Z, <i> et al.</i>: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. <i>Lancet Oncol.</i> 2009; <b>10</b>(1): 25–34. <a target=xrefwindow id=d11518e2018 href="http://www.ncbi.nlm.nih.gov/pubmed/19095497">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2021 href="https://doi.org/10.1016/S1470-2045(08)70285-7">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d11518e2030 class=n-a></a>Bruix J, Cheng AL, Meinhardt G, <i> et al.</i>: Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. <i>J Hepatol.</i> 2017; <b>67</b>(5): 999–1008. <a target=xrefwindow id=d11518e2041 href="http://www.ncbi.nlm.nih.gov/pubmed/28687477">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2044 href="https://doi.org/10.1016/j.jhep.2017.06.026">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d11518e2053 class=n-a></a>Reig M, Torres F, Rodriguez-Lope C, <i> et al.</i>: Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>J Hepatol.</i> 2014; <b>61</b>(2): 318–24. <a target=xrefwindow id=d11518e2064 href="http://www.ncbi.nlm.nih.gov/pubmed/24703956">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2067 href="https://doi.org/10.1016/j.jhep.2014.03.030">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d11518e2076 class=n-a></a>Rimola J, Díaz-González A, Darnell A, <i> et al.</i>: Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. <i>Hepatology.</i> 2018; <b>67</b>(2): 612–22. <a target=xrefwindow id=d11518e2087 href="http://www.ncbi.nlm.nih.gov/pubmed/28898447">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2090 href="https://doi.org/10.1002/hep.29515">Publisher Full Text </a></span><div class=note><a name=d11518e2093 class=n-a></a><p class=first id=d11518e2094><a target=xrefwindow href="https://facultyopinions.com/prime/731115695" id=d11518e2095>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d11518e2105 class=n-a></a>Cheng AL, Kang YK, Lin DY, <i> et al.</i>: Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. <i>J Clin Oncol.</i> 2013; <b>31</b>(32): 4067–75. <a target=xrefwindow id=d11518e2116 href="http://www.ncbi.nlm.nih.gov/pubmed/24081937">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2119 href="https://doi.org/10.1200/JCO.2012.45.8372">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d11518e2128 class=n-a></a>Johnson PJ, Qin S, Park JW, <i> et al.</i>: Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study. <i>JCO.</i> 2013; <b>31</b>(28): 3517–24. <a target=xrefwindow id=d11518e2139 href="http://www.ncbi.nlm.nih.gov/pubmed/23980084">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2142 href="https://doi.org/10.1200/JCO.2012.48.4410">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d11518e2151 class=n-a></a>Cainap C, Qin S, Huang WT, <i> et al.</i>: Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. <i>J Clin Oncol.</i> 2015; <b>33</b>(2): 172–9. <a target=xrefwindow id=d11518e2162 href="http://www.ncbi.nlm.nih.gov/pubmed/25488963">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2165 href="https://doi.org/10.1200/JCO.2013.54.3298">Publisher Full Text </a> | <a target=xrefwindow id=d11518e2169 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4279237">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d11518e2178 class=n-a></a>Zhu AX, Kudo M, Assenat E, <i> et al.</i>: Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. <i>JAMA.</i> 2014; <b>312</b>(1): 57–67. <a target=xrefwindow id=d11518e2189 href="http://www.ncbi.nlm.nih.gov/pubmed/25058218">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2192 href="https://doi.org/10.1001/jama.2014.7189">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d11518e2201 class=n-a></a>Rimassa L, Assenat E, Peck-Radosavljevic M, <i> et al.</i>: Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): A final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncol.</i> 2018; <b>19</b>(5): 682–93. <a target=xrefwindow id=d11518e2212 href="http://www.ncbi.nlm.nih.gov/pubmed/29625879">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2215 href="https://doi.org/10.1016/S1470-2045(18)30146-3">Publisher Full Text </a></span><div class=note><a name=d11518e2218 class=n-a></a><p class=first id=d11518e2219><a target=xrefwindow href="https://facultyopinions.com/prime/732998494" id=d11518e2220>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d11518e2229 class=n-a></a>Kudo M, Finn RS, Qin S, <i> et al.</i>: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. <i>Lancet.</i> 2018; <b>391</b>(10126): 1163–73. <a target=xrefwindow id=d11518e2240 href="http://www.ncbi.nlm.nih.gov/pubmed/29433850">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2243 href="https://doi.org/10.1016/S0140-6736(18)30207-1">Publisher Full Text </a></span><div class=note><a name=d11518e2245 class=n-a></a><p class=first id=d11518e2246><a target=xrefwindow href="https://facultyopinions.com/prime/732647407" id=d11518e2247>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d11518e2257 class=n-a></a>Bruix J, Qin S, Merle P, <i> et al.</i>: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet.</i> 2017; <b>389</b>(10064): 56–66. <a target=xrefwindow id=d11518e2268 href="http://www.ncbi.nlm.nih.gov/pubmed/27932229">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2271 href="https://doi.org/10.1016/S0140-6736(16)32453-9">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d11518e2280 class=n-a></a>Abou-Alfa GK, Meyer T, Cheng AL, <i> et al.</i>: Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>N Engl J Med.</i> 2018; <b>379</b>(1): 54–63. <a target=xrefwindow id=d11518e2291 href="http://www.ncbi.nlm.nih.gov/pubmed/29972759">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2294 href="https://doi.org/10.1056/NEJMoa1717002">Publisher Full Text </a></span><div class=note><a name=d11518e2296 class=n-a></a><p class=first id=d11518e2297><a target=xrefwindow href="https://facultyopinions.com/prime/733576189" id=d11518e2298>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d11518e2307 class=n-a></a>Zhu AX, Park JO, Ryoo BY, <i> et al.</i>: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial. <i> Lancet Oncol.</i> 2015; <b>16</b>(7): 859–70. <a target=xrefwindow id=d11518e2318 href="http://www.ncbi.nlm.nih.gov/pubmed/26095784">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2321 href="https://doi.org/10.1016/S1470-2045(15)00050-9">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d11518e2330 class=n-a></a>Zhu AX, Kang YK, Yen CJ, <i> et al.</i>: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncol.</i> 2019; <b>20</b>(2): 282–96. <a target=xrefwindow id=d11518e2341 href="http://www.ncbi.nlm.nih.gov/pubmed/30665869">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2344 href="https://doi.org/10.1016/S1470-2045(18)30937-9">Publisher Full Text </a></span><div class=note><a name=d11518e2346 class=n-a></a><p class=first id=d11518e2347><a target=xrefwindow href="https://facultyopinions.com/prime/734883889" id=d11518e2348>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d11518e2357 class=n-a></a>Kruger S, Ilmer M, Kobold S, <i> et al.</i>: Advances in cancer immunotherapy 2019 - latest trends. <i>J Exp Clin Cancer Res.</i> 2019; <b>38</b>(1): 268. <a target=xrefwindow id=d11518e2368 href="http://www.ncbi.nlm.nih.gov/pubmed/31217020">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2371 href="https://doi.org/10.1186/s13046-019-1266-0">Publisher Full Text </a> | <a target=xrefwindow id=d11518e2375 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6585101">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d11518e2384 class=n-a></a>Iñarrairaegui M, Melero I, Sangro B: Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes. <i>Clin Cancer Res.</i> 2018; <b>24</b>(7): 1518–24. <a target=xrefwindow id=d11518e2392 href="http://www.ncbi.nlm.nih.gov/pubmed/29138342">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2395 href="https://doi.org/10.1158/1078-0432.CCR-17-0289">Publisher Full Text </a></span><div class=note><a name=d11518e2397 class=n-a></a><p class=first id=d11518e2398><a target=xrefwindow href="https://facultyopinions.com/prime/732119329" id=d11518e2399>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d11518e2409 class=n-a></a>Yarchoan M, Xing D, Luan L, <i> et al.</i>: Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. <i>Clin Cancer Res.</i> 2017; <b>23</b>(23): 7333–9. <a target=xrefwindow id=d11518e2420 href="http://www.ncbi.nlm.nih.gov/pubmed/28928158">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2423 href="https://doi.org/10.1158/1078-0432.CCR-17-0950">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d11518e2432 class=n-a></a>Salmaninejad A, Valilou SF, Shabgah AG, <i> et al.</i>: PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. <i>J Cell Physiol.</i> 2019; <b>234</b>(10): 16824–37. <a target=xrefwindow id=d11518e2443 href="http://www.ncbi.nlm.nih.gov/pubmed/30784085">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2446 href="https://doi.org/10.1002/jcp.28358">Publisher Full Text </a></span><div class=note><a name=d11518e2448 class=n-a></a><p class=first id=d11518e2449><a target=xrefwindow href="https://facultyopinions.com/prime/735132164" id=d11518e2450>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d11518e2459 class=n-a></a>Buchbinder EI, Desai A: CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. <i>Am J Clin Oncol.</i> 2016; <b>39</b>(1): 98–106. <a target=xrefwindow id=d11518e2467 href="http://www.ncbi.nlm.nih.gov/pubmed/26558876">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2470 href="https://doi.org/10.1097/COC.0000000000000239">Publisher Full Text </a> | <a target=xrefwindow id=d11518e2473 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4892769">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d11518e2482 class=n-a></a>Sangro B, Gomez-Martin C, de La Mata M, <i> et al.</i>: A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. <i>J Hepatol.</i> 2013; <b>59</b>(1): 81–8. <a target=xrefwindow id=d11518e2493 href="http://www.ncbi.nlm.nih.gov/pubmed/23466307">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2496 href="https://doi.org/10.1016/j.jhep.2013.02.022">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d11518e2505 class=n-a></a>El-Khoueiry AB, Sangro B, Yau T, <i> et al.</i>: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet.</i> 2017; <b>389</b>(10088): 2492–502. <a target=xrefwindow id=d11518e2516 href="http://www.ncbi.nlm.nih.gov/pubmed/28434648">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2519 href="https://doi.org/10.1016/S0140-6736(17)31046-2">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d11518e2528 class=n-a></a>Yau T, Park JW, Finn RS, <i> et al.</i>: CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). <i>Ann Oncol.</i> 2019; <b>30</b>(Supplement 5): v874–v875. <a target=xrefwindow id=d11518e2539 href="https://doi.org/10.1093/annonc/mdz394.029">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d11518e2549 class=n-a></a>Zhu AX, Finn RS, Edeline J, <i> et al.</i>: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. <i>Lancet Oncol.</i> 2018; <b>19</b>(7): 940–52. <a target=xrefwindow id=d11518e2560 href="http://www.ncbi.nlm.nih.gov/pubmed/29875066">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2563 href="https://doi.org/10.1016/S1470-2045(18)30351-6">Publisher Full Text </a></span><div class=note><a name=d11518e2565 class=n-a></a><p class=first id=d11518e2566><a target=xrefwindow href="https://facultyopinions.com/prime/733372389" id=d11518e2567>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d11518e2576 class=n-a></a>Finn RS, Ryoo BY, Merle P, <i> et al.</i>: Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>J Clin Oncol.</i> 2020; <b>38</b>(3): 193–202. <a target=xrefwindow id=d11518e2587 href="http://www.ncbi.nlm.nih.gov/pubmed/31790344">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2590 href="https://doi.org/10.1200/JCO.19.01307">Publisher Full Text </a></span><div class=note><a name=d11518e2592 class=n-a></a><p class=first id=d11518e2593><a target=xrefwindow href="https://facultyopinions.com/prime/737027313" id=d11518e2594>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d11518e2603 class=n-a></a>Floudas CS, Xie C, Brar G, <i> et al.</i>: Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC). <i>JCO.</i> 2019; <b>37</b>(4_suppl): 336. <a target=xrefwindow id=d11518e2614 href="https://doi.org/10.1200/JCO.2019.37.4_suppl.336">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d11518e2623 class=n-a></a>Yau T, Kang YK, Kim TY, <i> et al.</i>: Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. <i>JCO.</i> 2019; <b>37</b>(15_suppl): 4012. <a target=xrefwindow id=d11518e2634 href="https://doi.org/10.1200/JCO.2019.37.15_suppl.4012">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d11518e2643 class=n-a></a>Brahmer JR, Lacchetti C, Schneider BJ, <i> et al.</i>: Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>J Clin Oncol.</i> 2018; <b>36</b>(17): 1714–68. <a target=xrefwindow id=d11518e2654 href="http://www.ncbi.nlm.nih.gov/pubmed/29442540">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2657 href="https://doi.org/10.1200/JCO.2017.77.6385">Publisher Full Text </a> | <a target=xrefwindow id=d11518e2661 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6481621">Free Full Text </a></span><div class=note><a name=d11518e2663 class=n-a></a><p class=first id=d11518e2664><a target=xrefwindow href="https://facultyopinions.com/prime/732664827" id=d11518e2665>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d11518e2674 class=n-a></a>Brown ZJ, Heinrich B, Steinberg SM, <i> et al.</i>: Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. <i>J Immunother Cancer.</i> 2017; <b>5</b>(1): 93. <a target=xrefwindow id=d11518e2685 href="http://www.ncbi.nlm.nih.gov/pubmed/29157287">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2688 href="https://doi.org/10.1186/s40425-017-0298-2">Publisher Full Text </a> | <a target=xrefwindow id=d11518e2692 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5697069">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d11518e2702 class=n-a></a>Kudo M, Arizumi T: Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2). <i>Oncology.</i> 2017; <b>93</b>(Suppl 1): 127–34. <a target=xrefwindow id=d11518e2710 href="http://www.ncbi.nlm.nih.gov/pubmed/29258086">PubMed Abstract </a> | <a target=xrefwindow id=d11518e2713 href="https://doi.org/10.1159/000481243">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d11518e2722 class=n-a></a>Stein S, Pishvaian MJ, Lee MS, <i> et al.</i>: Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). <i>JCO.</i> 2018; <b>36</b>(15_suppl): 4074. <a target=xrefwindow id=d11518e2733 href="https://doi.org/10.1200/JCO.2018.36.15_suppl.4074">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d11518e2742 class=n-a></a>Cheng AL, Qin S, Ikeda M, <i> et al.</i>: IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). <i>Ann Oncol.</i> 2019; <b>30</b>(Supplement 9): ix186–ix187. <a target=xrefwindow id=d11518e2753 href="https://doi.org/10.1093/annonc/mdz446.002">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 17 Jun 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-620/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-620/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong<br/> <sup>2</sup> State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong<br/> <p> <div class=margin-bottom> Kwan-Lung Ko <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Lung-Yi Mak <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Ka-Shing Cheung <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Man-Fung Yuen <br/> <span>Roles: </span> Conceptualization, Project Administration, Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-620/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 17 Jun 2020, 9:620 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.24543.1">https://doi.org/10.12688/f1000research.24543.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Ko KL <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=27074 data-id=24543 data-downloads="" data-views="" data-scholar="10.12688/f1000research.24543.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-620/v1/pdf?article_uuid=035be9ea-c7e2-4c84-9410-e9e2ac6bf73d" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.24543.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Ko KL, Mak LY, Cheung KS and Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):620 (<a href="https://doi.org/10.12688/f1000research.24543.1" target=_blank>https://doi.org/10.12688/f1000research.24543.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=24543 id=mobile-track-article-signin-24543 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/24543?target=/articles/9-620/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=27074 /> <input name=articleId type=hidden value=24543 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Guohong Han</strong>, Department of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Millitary Medical University, China </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Tim F. Greten</strong>, Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 17 Jun 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-620/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-620/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=58952-65020></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=69446-65021></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-620/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>17 Jun 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Guohong Han</strong>, Department of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Millitary Medical University, China </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Tim F. Greten</strong>, Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-620/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-620/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Hepatocellular carcinoma: recent advances...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-620/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-620/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-620/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Ko KL et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-620/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-620",
            templates : {
                twitter : "Hepatocellular carcinoma: recent advances and emerging medical.... Ko KL et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-620/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Hepatocellular carcinoma: recent advances and emerging medical therapies", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Hepatocellular carcinoma: recent advances and emerging medical therapies", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/24543/27074")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "27074");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "65020": 0,
                           "65021": 1,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "1b42ea59-4c8b-47eb-8f58-6195751ee54b";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-620.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-620.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-620.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-620.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-620.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>